Psychiatric disorders affect people around the world noticeably. Some of them tend to manifest together known as comorbidity conditions (
2). OCD and schizophrenia as widespread mental disorders are one of the important co-occurrence types (
3). OCD is identified by intrusive thoughts and the urge for reducing the unpleasant experience by different types of compulsions (
4). The patients suffer from recurrent invasive thoughts or stereotype behaviors at least one hour per day (
5). It is with the prevalence of about 1-3% in human population (
6,
7). On the other hand, schizophrenia is a sever condition of consciousness abnormalities including hallucinations, delusions, disorganized communication, poor planning, reduced motivation, and blunted affect with 0.5% and 1% lifetime worldwide prevalence (
8,
9). Both disorders have demonstrated heterogeneity in genetic concept and clinical phenotype (
10,
11). About 30.3% of patients diagnosed with schizophrenia have the obsessive-compulsive symptoms (OCS) and about 13.6% of them shows co-occurrence with OCD (
12). In fact, OCD can be accounted as schizophrenia risk factor (
3). There are some common features between OCD and schizophrenia despite the different diagnostic entities. Some symptoms, age of onset, gender, and structural impairment in brain including areas of prefrontal cortex, anterior cingulate, caudate nucleus and thalamus are shared in OCD and schizophrenia. The patients with two disorders, schizo-OCD, have more difficulties in prognosis, treatment responses, and lower quality of life (
13). In addition, some of the applied therapeutic methods are also similar (
14). Therefore, the disorders may have same molecular origin as they have a tendency of comorbidity (
15). Some pathways of serotonin, dopamine and glutamine are reported common between two disorders. The most applied medications for schizophrenia-OCD comorbidity belong to selective serotonin re-uptake inhibitors (SSRI) family (
16,
17). It must be noted that some of patients were not responded to treatment. In addition, some other types of drugs affecting on dopamine receptors (antagonism) also showed effective in patients with OCD (
18). Antipsychotic medications, which substantially act as dopamine antagonism, are also effective in patients with schizophrenia (
19). Particularly, Clozapine and Olanzapine as dopamine antagonism seemed valuable with or without SSRIs application in some schizophrenia patients (
20). Both drugs act as D2 receptors antagonisms in the mesolimbic pathway; in addition, they have high affinity to 5-HT2A receptors in the frontal cortex as well (
21). However, Clozapine and Olanzapine can increase the risk of obsessive-compulsive symptoms in schizophrenia patients (
22). Proteomics, genomics, and protein-protein interaction (
1) network analysis can provide a new insight of interactome profile of the two disorders (
23,
24). Central genes in OCD comorbid schizophrenia PPI network are essentials in the network integrity and can be targets for more analysis (
25). Since there are crucial genes among query and added genes which play significant role in disorder PPI network analysis is a useful tool to explore the critical genes. It is essential to evaluate the structural and functional properties of the related significant genes to decipher the core underling mechanisms of pathogenesis of the OCD and schizophrenia. Furthermore, the analysis of essential genes in the network can provide a new insight in drug targeting strategies.